January 26, 2018 Clinical Research/Diagn. Environ, Ag./Food & Bev Licensing, IP, and Legal PR/Corporate

Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that a federal jury in San Francisco has ruled in its favor in a patent infringement suit filed against Ariosa Diagnostics, Inc., now owned by Roche. The jury found that both Ariosa’s previous and current version of the Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430... Read more

January 26, 2018 Licensing, IP, and Legal

Invitation to Roche's Virtual Pipeline Event

Basel, 26 January 2018 Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event in a... Read more

January 22, 2018 Clinical Research/Diagn. Lab Equipment Licensing, IP, and Legal

Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market

HERCULES, Calif. — January 22, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System... Read more

January 12, 2018 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more

January 12, 2018 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Chicago, USA Jan 8, 2018 – GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients. The two companies... Read more